Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 4/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 10/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PROC | P04070 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640158 | 0.88 | F10 (0.52) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL2640150 | 0.87 | HTR1A (0.53) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL2640127 | 0.86 | HTR1A (0.48) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL7420409 | 0.84 | HTR1A (0.53) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL2638974 | 0.84 | HTR1A (0.47) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL6217888 | 0.84 | CD274 (0.37) | HTR1AHTR1DHTR2CKLKB1MAPT | |
| SCHEMBL6212650 | 0.84 | F10 (0.51) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL2640085 | 0.83 | HTR1A (0.47) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL2640100 | 0.83 | HTR1A (0.45) | HTR1AHTR1DHTR2CF10KLKB1 | |
| SCHEMBL2639307 | 0.83 | HTR1A (0.45) | HTR1AHTR1DHTR2CF10KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599918-B2 | Inhibit Factor Xa Factor IIa (thrombin) | AVENTIS PHARMACEUTICALS INC. | 2003-07-29 | — | — | US | claimed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | claimed |
| EP-1222182-B1 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMA INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6599918-B2 | Inhibit Factor Xa Factor IIa (thrombin) | AVENTIS PHARMACEUTICALS INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | F2, TFPI, F3 | HTR1A 1462/4885HTR1D 2054/4885HTR2C 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.